JP4912153B2 - タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法 - Google Patents

タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法 Download PDF

Info

Publication number
JP4912153B2
JP4912153B2 JP2006542675A JP2006542675A JP4912153B2 JP 4912153 B2 JP4912153 B2 JP 4912153B2 JP 2006542675 A JP2006542675 A JP 2006542675A JP 2006542675 A JP2006542675 A JP 2006542675A JP 4912153 B2 JP4912153 B2 JP 4912153B2
Authority
JP
Japan
Prior art keywords
conjugate
virus
antibody
dota
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006542675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535492A (ja
JP2007535492A5 (https=
Inventor
グリフィス,ゲイリー・エル
ゴヴィンダン,セレングラム・ヴイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of JP2007535492A publication Critical patent/JP2007535492A/ja
Publication of JP2007535492A5 publication Critical patent/JP2007535492A5/ja
Application granted granted Critical
Publication of JP4912153B2 publication Critical patent/JP4912153B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006542675A 2003-12-01 2004-12-01 タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法 Expired - Fee Related JP4912153B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52604403P 2003-12-01 2003-12-01
US60/526,044 2003-12-01
PCT/US2004/040046 WO2005084179A2 (en) 2003-12-01 2004-12-01 Improved method for preparing conjugates of proteins and chelating agents

Publications (3)

Publication Number Publication Date
JP2007535492A JP2007535492A (ja) 2007-12-06
JP2007535492A5 JP2007535492A5 (https=) 2011-06-16
JP4912153B2 true JP4912153B2 (ja) 2012-04-11

Family

ID=34919313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542675A Expired - Fee Related JP4912153B2 (ja) 2003-12-01 2004-12-01 タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法

Country Status (4)

Country Link
US (1) US7259249B2 (https=)
EP (2) EP2962699A3 (https=)
JP (1) JP4912153B2 (https=)
WO (1) WO2005084179A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7524570B2 (en) * 2005-10-13 2009-04-28 Hitachi Global Storage Technologies Netherlands B.V. Perpendicular magnetic recording system and medium with high-moment corrosion-resistant “soft” underlayer (SUL)
JP5730581B2 (ja) 2008-01-08 2015-06-10 ランセウス メディカル イメージング, インコーポレイテッド 造影剤としてのn−アルコキシアミド抱合体
US20100247484A1 (en) * 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
WO2011005322A2 (en) * 2009-07-08 2011-01-13 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
LT2535358T (lt) * 2010-02-10 2018-03-26 Fujifilm Ri Pharma Co., Ltd. Radioaktyvus metalu žymėtas anti-kadherino antikūnas
US10363323B2 (en) 2011-02-10 2019-07-30 Ruprecht-Karls-Universitat Heidelberg Hydrophobic modified peptides for liver specific diagnosis
CA2898146C (en) * 2012-12-19 2020-12-01 Charles Andrew BOSWELL Methods and compositions for radiohalogen protein labeling
EP3010549A4 (en) * 2013-06-17 2017-03-15 Emory University Pathogen binding agents conjugated to radioisotopes and uses in imaging and therapeutic applications
EP2873679A1 (en) * 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
WO2017161356A1 (en) * 2016-03-18 2017-09-21 Wake Forest University Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CA3148288A1 (en) * 2019-08-21 2021-02-25 Nihon Medi-Physics Co., Ltd. Method for producing radioactive metal complex
WO2022149578A1 (ja) * 2021-01-08 2022-07-14 日本メジフィジックス株式会社 Ac-225溶液の製造方法およびAc-225溶液を用いた医薬の製造方法
AU2023242087A1 (en) * 2022-03-30 2024-09-12 Nihon Medi-Physics Co., Ltd. Method for producing complex

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5556982A (en) 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4824986A (en) 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
NZ212437A (en) 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5271927A (en) 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
GB8603537D0 (en) 1986-02-13 1986-03-19 Parker D Conjugate compound
US5082930A (en) 1986-05-29 1992-01-21 Mallinckrodt Medical, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4861869A (en) 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5057302A (en) 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
WO1988007553A1 (fr) * 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5612016A (en) 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
CA1341373C (en) 1988-06-24 2002-07-02 Roberta C. Cheng Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5112953A (en) 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5310535A (en) 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
JPH05344899A (ja) 1992-06-11 1993-12-27 Kokuritsu Yobou Eisei Kenkyusho C型肝炎ウイルス外被タンパク質の産生法
US5760191A (en) 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
WO2003048207A2 (en) * 2001-11-28 2003-06-12 Immunomedics, Inc. Anti-dota antibody

Also Published As

Publication number Publication date
WO2005084179A2 (en) 2005-09-15
JP2007535492A (ja) 2007-12-06
US7259249B2 (en) 2007-08-21
EP2962699A2 (en) 2016-01-06
US20050191239A1 (en) 2005-09-01
EP2962699A3 (en) 2016-04-06
EP1689448A2 (en) 2006-08-16
EP1689448B1 (en) 2015-07-29
WO2005084179A3 (en) 2006-03-16
EP1689448A4 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
JP4912153B2 (ja) タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
JP7637431B2 (ja) 分岐連結体を備えたチューブリシン類縁体の共役体
JP6133431B2 (ja) 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US11873281B2 (en) Conjugates of cell binding molecules with cytotoxic agents
JP2025143317A (ja) ポリペプチドの放射性標識
JP4732331B2 (ja) 安定な放射性ヨウ素複合体の精製方法
JP2024028815A (ja) チューブリシン類縁体と細胞結合分子との共役体の製剤
AU2019452577B2 (en) Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor
JP6944720B2 (ja) リジン−尿素−グルタメートファーマコフォアを含む修飾デキストラン複合体
WO2022101771A1 (en) Macrocyclic compounds and methods of use thereof
TW202325343A (zh) 去醣基化抗體之放射性複合體,及放射性醫藥
JPH11513374A (ja) (放射性)標識化ビオチン誘導体類
KR100238558B1 (ko) 단백질의 테크네튬-99m 표지화
EP4327831A1 (en) Radioactive complex of anti-cd20 antibody, and radiopharmaceutical
JP2002524470A (ja) 二機能性抗体および標的化抗腫瘍剤におけるその使用
WO2022211051A1 (ja) 抗egfr抗体の放射性複合体、及び、放射性医薬
EA045797B1 (ru) Радиоактивное мечение полипептидов
CN117769440A (zh) 抗cd20抗体的放射性复合物和放射性药物
HK40069011A (en) Cell-binding molecule-tubulysin derivative conjugate and preparation method therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110324

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111226

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120117

R150 Certificate of patent or registration of utility model

Ref document number: 4912153

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150127

Year of fee payment: 3

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees